Significant Nationwide Variability exists in the Costs and in Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample (NIS) Database

Multiple myeloma (MM) is a rare cancer with an annual incidence of 30,000, comprising 1% of all cancer in the United States [1]. Recent advances in MM treatment and supportive care have improved overall survival (OS) outcomes for patients; however, the causes of variation in survival outcomes among treatment centers have not been extensively evaluated.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research